FSTL1 and myocardial infarction: Preclinical studies using recombinant FSTL1 delivery, FSTL1-overexpressing models, and exercise interventions have consistently demonstrated improved cardiac angiogenesis, reduced fibrosis, and enhanced functional recovery post-MI.